scholarly journals A Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavy-Drinking Alcohol-Dependent Patients

2011 ◽  
Vol 36 (3) ◽  
pp. 406-416 ◽  
Author(s):  
Raye Z. Litten ◽  
Joanne B. Fertig ◽  
Daniel E. Falk ◽  
Megan L. Ryan ◽  
Margaret E. Mattson ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Heavy Drinking ◽  
Drinking Alcohol ◽  
Double Blind ◽  
Quetiapine Fumarate ◽  
Double Blind Placebo ◽  
Alcohol Dependent

scholarly journals Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial

2018 ◽  
Vol 212 (6) ◽  
pp. 362-369 ◽  
Author(s):  
Kirsten C. Morley ◽  
Andrew Baillie ◽  
Isabel Fraser ◽  
Ainsley Furneaux-Bate ◽  
Glenys Dore ◽  
...  
Keyword(s):  
Liver Disease ◽  
Alcohol Dependence ◽  
Controlled Trial ◽  
Heavy Drinking ◽  
Randomised Clinical Trial ◽  
Effective Treatment Option ◽  
Double Blind ◽  
Significant Treatment ◽  
Double Blind Placebo ◽  
Specialist Services

BackgroundThere are no available medications for the management of alcohol dependence for patients with alcoholic liver disease (ALD).AimsTo conduct a multisite, double blind, placebo-controlled, randomised clinical trial of baclofen in the treatment of alcohol dependence, with or without liver disease (trial registration: ClinicalTrials.gov, NCT01711125).MethodPatients (n= 104) were randomised to placebo, baclofen 30 mg/day or 75 mg/day for 12 weeks. Primary outcomes included survival time to lapse (any drinking), relapse (≥5 drinks per day in men and ≥4 in women), and the composite outcome of drinks per drinking day, number of heavy drinking days, and percentage days abstinent.ResultsThere was a significant effect of baclofen (composite groups) on time to lapse (χ2= 6.44,P<0.05, Cohen'sd= 0.56) and relapse (χ2= 4.62,P<0.05,d= 0.52). A significant treatment effect of baclofen was observed for percentage days abstinent (placebo 43%, baclofen 30 mg 69%, baclofen 75 mg 65%;P<0.05). There was one serious adverse event (overdose) directly related to medication (75 mg).ConclusionsBaclofen may be an effective treatment option for patients with ALD. However, given the profile of adverse events, the role for this medication might be best limited to specialist services.Declaration of interestNone.

scholarly journals Safety Assessment of Liver Injury with Quetiapine Fumarate XR Management in Very Heavy Drinking Alcohol-Dependent Patients

2016 ◽  
Vol 36 (11) ◽  
pp. 935-944 ◽  
Author(s):  
Vatsalya Vatsalya ◽  
Akash Pandey ◽  
Melanie L. Schwandt ◽  
Matthew C. Cave ◽  
Shirish S. Barve ◽  
...  
Keyword(s):  
Liver Injury ◽  
Safety Assessment ◽  
Heavy Drinking ◽  
Drinking Alcohol ◽  
Quetiapine Fumarate ◽  
Alcohol Dependent

Nefazodone Treatment of Major Depression in Alcohol-Dependent Patients: A Double-Blind, Placebo-Controlled Trial

2000 ◽  
Vol 20 (2) ◽  
pp. 129-136 ◽  
Author(s):  
Peter P. Roy-Byrne ◽  
Kenneth P. Pages ◽  
Joan E. Russo ◽  
Craig Jaffe ◽  
Arthur W. Blume ◽  
...  
Keyword(s):  
Major Depression ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Alcohol Dependent

Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial

1997 ◽  
Vol 27 (8) ◽  
pp. 860-867 ◽  
Author(s):  
V.A. VARNEY ◽  
J. EDWARDS ◽  
K. TABBAH ◽  
H. BREWSTER ◽  
G. MAVROLEON ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Specific Immunotherapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

A randomized double blind, placebo controlled trial of a Chinese herbal preparation (CH100) in chronic Hepatitis C

2001 ◽  
Vol 120 (5) ◽  
pp. A384-A384
Author(s):  
L MOLLISON ◽  
L TOTTEN ◽  
C HOVELL ◽  
K THAYNE ◽  
C CONNELLY ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Controlled Trial ◽  
Herbal Preparation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Chinese Herbal
Sign in / Sign up

Export Citation Format

Share Document